» Articles » PMID: 7875641

Pharmacokinetics of Cyclophosphamide in Patients with Systemic Necrotizing Angiitis

Overview
Specialty Pharmacology
Date 1994 Jan 1
PMID 7875641
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclophosphamide pharmacokinetics were investigated following administration to patients with systemic necrotizing angiitis. Ten patients (eight women and two men) received cyclophosphamide as a 1-h-rate-constant intravenous infusion at doses ranging from 600 to 1200 mg. All patients received concomitant oral prednisone (1 mg/kg/d). Blood samples were collected at the end of drug infusion and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24 h later. Serum cyclophosphamide concentrations were assayed by high pressure liquid chromatography. The peak serum cyclophosphamide levels ranged from 15.7 to 29.4 mg/L. The mean cyclophosphamide elimination half-life was 6.2 +/- 1.3 h (mean +/- SD). The mean apparent volume of distribution and mean total plasma clearance were, respectively, 0.75 +/- 0.22 L/kg (mean +/- SD) and 83 +/- 22 mL/min (mean +/- SD). These results obtained in systemic vasculitic diseases were consistent with those observed in other studies with cancer patients receiving comparable doses of cyclophosphamide.

Citing Articles

Ovarian protection in cyclophosphamide-treated mice by fennel.

Hassanpour A, Yousefian S, Askaripour M, Sharififar F, Ezzatabadipour M Toxicol Rep. 2017; 4:160-164.

PMID: 28959636 PMC: 5615121. DOI: 10.1016/j.toxrep.2017.03.002.


Clinical pharmacokinetics of cyclophosphamide.

de Jonge M, Huitema A, Rodenhuis S, Beijnen J Clin Pharmacokinet. 2005; 44(11):1135-64.

PMID: 16231966 DOI: 10.2165/00003088-200544110-00003.


Optimisation of cyclophosphamide therapy in systemic vasculitis.

Richmond R, McMillan T, Luqmani R Clin Pharmacokinet. 1998; 34(1):79-90.

PMID: 9474474 DOI: 10.2165/00003088-199834010-00004.